 | • レポートコード：MRC2212A151 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、236ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥732,452 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,472,452 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に1,004.23百万ドルであった世界の希少疾患遺伝子検査市場規模が、2022年に1,157.97百万ドルへと拡大し、2027年までにCAGR 15.56％で成長して2,392.16百万ドルに達すると予測しています。当書は、希少疾患遺伝子検査の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、疾患別（癌、心血管疾患、皮膚科疾患、内分泌・代謝疾患、血液疾患）分析、技術別（アレイ技術、FISH、核型分析、次世代シーケンシング、PCR）分析、専門分野別（生化学的遺伝子検査、染色体遺伝子検査、分子遺伝学的検査）分析、エンドユーザー別（診断研究室、病院＆クリニック、実験室＆CRO）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめております。なお、当書に掲載されている企業情報には、23&Me Inc.、3billion, Inc.、Associated Regional and University Pathologists, Inc.、Baylor Miraca Genetics Laboratories, LLC、Centogene N.V.、Color Genomics, Inc.、Coopersurgical, Inc.、Eurofins Scientific SE、Fulgent Genetics, Inc、Health Network Laboratories, L.Pなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の希少疾患遺伝子検査市場規模：疾患別 - 癌における市場規模 - 心血管疾患における市場規模 - 皮膚科疾患における市場規模 - 内分泌・代謝疾患における市場規模 - 血液疾患における市場規模 ・世界の希少疾患遺伝子検査市場規模：技術別 - アレイ技術の市場規模 - FISHの市場規模 - 核型分析の市場規模 - 次世代シーケンシングの市場規模 - PCRの市場規模 ・世界の希少疾患遺伝子検査市場規模：専門分野別 - 生化学的遺伝子検査の市場規模 - 染色体遺伝子検査の市場規模 - 分子遺伝学的検査の市場規模 ・世界の希少疾患遺伝子検査市場規模：エンドユーザー別 - 診断研究室における市場規模 - 病院＆クリニックにおける市場規模 - 実験室＆CROにおける市場規模 ・世界の希少疾患遺伝子検査市場規模：地域別 - 南北アメリカの希少疾患遺伝子検査市場規模 アメリカの希少疾患遺伝子検査市場規模 カナダの希少疾患遺伝子検査市場規模 ブラジルの希少疾患遺伝子検査市場規模 ... - アジア太平洋の希少疾患遺伝子検査市場規模 日本の希少疾患遺伝子検査市場規模 中国の希少疾患遺伝子検査市場規模 インドの希少疾患遺伝子検査市場規模 韓国の希少疾患遺伝子検査市場規模 台湾の希少疾患遺伝子検査市場規模 ... - ヨーロッパ/中東/アフリカの希少疾患遺伝子検査市場規模 イギリスの希少疾患遺伝子検査市場規模 ドイツの希少疾患遺伝子検査市場規模 フランスの希少疾患遺伝子検査市場規模 ロシアの希少疾患遺伝子検査市場規模 ... - その他地域の希少疾患遺伝子検査市場規模 ・競争状況 ・企業情報 |
The Global Rare Disease Genetic Testing Market size was estimated at USD 1,004.23 million in 2021 and expected to reach USD 1,157.97 million in 2022, and is projected to grow at a CAGR 15.56% to reach USD 2,392.16 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Rare Disease Genetic Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Disease Type, the market was studied across Cancer, Cardiovascular Disorders, Dermatology Diseases, Endocrine & Metabolism Diseases, Hematology Diseases, Immunological Disorders, Musculoskeletal Disorders, and Neurological Disorders.
Based on Technology, the market was studied across Array Technology, FISH, Karyotyping, Next Generation Sequencing, PCR – based Testing, and Sanger Sequencing. The Next Generation Sequencing is further studied across Whole Exome Sequencing and Whole Genome Sequencing.
Based on Specialty, the market was studied across Biochemical Genetic Tests, Chromosomal Genetic Tests, and Molecular Genetic Tests.
Based on End-user, the market was studied across Diagnostic Laboratories, Hospitals & Clinics, and Research Laboratories & CROs.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Rare Disease Genetic Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Rare Disease Genetic Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Rare Disease Genetic Testing Market, including 23&Me Inc., 3billion, Inc., Associated Regional and University Pathologists, Inc., Baylor Miraca Genetics Laboratories, LLC, Centogene N.V., Color Genomics, Inc., Coopersurgical, Inc., Eurofins Scientific SE, Fulgent Genetics, Inc, Health Network Laboratories, L.P., Invitae Corporation, Laboratory Corporation of America Holdings, Macrogen, Inc., Myriad Genetics, Inc., OPKO Health, Inc., PerkinElmer Inc., PreventionGenetics LLC, Progenity, Inc., Quest Diagnostics Incorporated, Sanofi S.A., and Strand Life Sciences Pvt. Ltd..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Rare Disease Genetic Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Rare Disease Genetic Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Rare Disease Genetic Testing Market?
4. What is the competitive strategic window for opportunities in the Global Rare Disease Genetic Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Rare Disease Genetic Testing Market?
6. What is the market share of the leading vendors in the Global Rare Disease Genetic Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Rare Disease Genetic Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rapidly increasing use in rare disease diagnostics including personalized medicines
5.1.1.2. Recent developments of novel platforms in disease diagnosis
5.1.1.3. Growing patient registry for rare disease
5.1.2. Restraints
5.1.2.1. Inadequacy of effective diagnosis framework
5.1.3. Opportunities
5.1.3.1. Advancements in genetic technology to identify new rare disease genes
5.1.3.2. Government assistance for rare disease diagnosis
5.1.4. Challenges
5.1.4.1. Lack of awareness pertaining to the rare disease conditions
5.1.4.2. Technical challenges incorporated with genetic tests & data management
5.2. Cumulative Impact of COVID-19
6. Rare Disease Genetic Testing Market, by Disease Type
6.1. Introduction
6.2. Cancer
6.3. Cardiovascular Disorders
6.4. Dermatology Diseases
6.5. Endocrine & Metabolism Diseases
6.6. Hematology Diseases
6.7. Immunological Disorders
6.8. Musculoskeletal Disorders
6.9. Neurological Disorders
7. Rare Disease Genetic Testing Market, by Technology
7.1. Introduction
7.2. Array Technology
7.3. FISH
7.4. Karyotyping
7.5. Next Generation Sequencing
7.6.1. Whole Exome Sequencing
7.6.2. Whole Genome Sequencing
7.6. PCR – based Testing
7.7. Sanger Sequencing
8. Rare Disease Genetic Testing Market, by Specialty
8.1. Introduction
8.2. Biochemical Genetic Tests
8.3. Chromosomal Genetic Tests
8.4. Molecular Genetic Tests
9. Rare Disease Genetic Testing Market, by End-user
9.1. Introduction
9.2. Diagnostic Laboratories
9.3. Hospitals & Clinics
9.4. Research Laboratories & CROs
10. Americas Rare Disease Genetic Testing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Rare Disease Genetic Testing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Rare Disease Genetic Testing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 23&Me Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. 3billion, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Associated Regional and University Pathologists, Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Baylor Miraca Genetics Laboratories, LLC
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Centogene N.V.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Color Genomics, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Coopersurgical, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Eurofins Scientific SE
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Fulgent Genetics, Inc
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Health Network Laboratories, L.P.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Invitae Corporation
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Laboratory Corporation of America Holdings
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Macrogen, Inc.
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Myriad Genetics, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. OPKO Health, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. PerkinElmer Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. PreventionGenetics LLC
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Progenity, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Quest Diagnostics Incorporated
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sanofi S.A.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Strand Life Sciences Pvt. Ltd.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing